'In­spired' by Ipsen's mis­sion, San­dra Sil­vestri joins as next CMO; Ex­i­cure's slide con­tin­ues with CEO, CFO ex­its

Ipsen is wait­ing on an FDA de­ci­sion this sum­mer for what could be the first drug to treat an ul­tra-rare bone dis­ease called fi­brodys­pla­sia os­si­f­i­cans pro­gres­si­va (FOP) — and if all goes well, it will have a new chief med­ical of­fi­cer to take it across the fin­ish line.

San­dra Sil­vestri is join­ing the com­pa­ny from Sanofi on May 5, Ipsen an­nounced ear­li­er this week. An en­docri­nol­o­gist by train­ing, her re­sume boasts long tenures at both Eli Lil­ly and Sanofi, where she was most re­cent­ly the French phar­ma’s se­nior VP and CMO of its Gen­er­al Med­i­cines glob­al busi­ness unit and glob­al head of med­ical af­fairs ca­pa­bil­i­ties at its Cen­tre of Ex­cel­lence and Med­ical Hub.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER